New syringe design tested for common eye disease treatment
NCT ID NCT05112861
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a pre-filled syringe is as safe as the traditional vial when giving the medicine bevacizumab for certain eye diseases. About 120 people with wet age-related macular degeneration, diabetic macular edema, or branch retinal vein occlusion will receive injections into the eye. The main goal is to compare side effects between the two delivery methods over 3 months.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Clinical Site
Springfield, Illinois, 62704, United States
-
Clinical Site
Hagerstown, Maryland, 21740, United States
-
Clinical Site
Chambersburg, Pennsylvania, 17201, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Longer-Lasting eye injection could cut treatment visits for macular disease
- Can a VR maze reveal hidden vision loss in macular degeneration?
- Can a new eye injection preserve vision in south asians with diabetes?
- Laser zap before eye injection could cut needle count for wet AMD
- Could a biosimilar eye injection offer a new way to treat diabetic macular edema?
- Can a new eye injection save vision in wet AMD?